Regulatory Approach for Biosimilars

Regulatory Approach for Biosimilars Photo
This systems administration meet will give a magnificent chance to the researchers, accomplices and pharma  pioneers from Biopharmaceutical and Biotechnology businesses to talk about and find out about the administrative capabilities required for Biosimilars and Biologics. This track incorporates: Licensing of biosimilars, Biosimilars direction, Biosimilar Patents , BLA petitioning for biosimilars, Regulatory prospects of BRIC nations, a worldview of customary generics to biosimilars, Biowaiver endorsement for Biosimilars. Around 20% of the biologics and biosimilars in the overall R&D pipelines are confronting difficulties to fall in accordance with the administrative rules.
  • Licensing of Biosimilars
  • Biosimilars regulation
  • Patent issues
  • BLA filing for biosimilars
  • Regulatory prospects of BRIC countries
  • A paradigm of traditional generics to biosimilars
  • Generic Biosimilars
  • Consideration of biowaiver extensions for BCS class III drugs

Are you interested in

Mail us at

Programs & Speaking Engagement
biosimilars@alliedmeetings.com
Sponsorship
john.wilson@alliedmeetings.com
Group Discounts and Delegates
biosimilars@alliedmeetings.com
More details about sponsorship:sponsors@alliedacademies.com

Authorization Policy

By registering for the conference you grant permission to Allied Academies to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute,broadcast,edit and/or digitize the resulting images and materials in publications, advertising materials,or in any other form worldwide without compensation. Taking of photographs and/or video taping during any session is prohibited. Contact us for any queries
Copyright © 2017-2018 Allied Academies, All Rights Reserved.